scholarly journals Cardiomyocyte-Specific Deletion of Gsk3α Mitigates Post–Myocardial Infarction Remodeling, Contractile Dysfunction, and Heart Failure

2014 ◽  
Vol 64 (7) ◽  
pp. 696-706 ◽  
Author(s):  
Firdos Ahmad ◽  
Hind Lal ◽  
Jibin Zhou ◽  
Ronald J. Vagnozzi ◽  
Justine E. Yu ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Post Myocardial Infarction ◽  
Contractile Dysfunction ◽  
Specific Deletion

Levosimendan improves contractilityin vivoandin vitroin a rodent model of post-myocardial infarction heart failure

2014 ◽  
Vol 210 (4) ◽  
pp. 865-874 ◽  
Author(s):  
S. M. Kolseth ◽  
N. P. L. Rolim ◽  
Ø. Salvesen ◽  
D. O. Nordhaug ◽  
A. Wahba ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Rodent Model ◽  
Post Myocardial Infarction ◽  
Infarction Heart

Mineralocorticoid receptor antagonists

ESC CardioMed ◽  
2018 ◽  
pp. 167-173
Author(s):  
Faiez Zannad ◽  
João Pedro Ferreira
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Adverse Effects ◽  
Beneficial Effect ◽  
Mechanism Of Action ◽  
Mineralocorticoid Receptor ◽  
Post Myocardial Infarction ◽  
Mineralocorticoid Receptor Antagonists ◽  
Receptor Antagonists ◽  
Clinical Syndromes

Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines while recommending a MRA do not make a clear recommendation as to which MRA should be used, how doses should be titrated, or which monitorization is indicated. This chapter provides an appraisal of the different types of MRA drugs and their pharmacological differences with respect to mechanism of action, pharmacokinetics, monitoring, adverse effects, and drug interactions.

Sign in / Sign up

Export Citation Format

Share Document